Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
21 mars 2023 08h30 HE
|
Ultragenyx Pharmaceutical Inc.
NOVATO, Calif., March 21, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for...
Ultragenyx Appoints Dr. Eric Crombez Chief Medical Officer and Executive Vice President
14 mars 2023 08h30 HE
|
Ultragenyx Pharmaceutical Inc.
NOVATO, Calif., March 14, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) announced that Eric Crombez, M.D., has been promoted to chief medical officer and executive vice...
Ultragenyx to Participate in Orphan Neuro Panel at Cowen Healthcare Conference
28 févr. 2023 16h01 HE
|
Ultragenyx Pharmaceutical Inc.
NOVATO, Calif., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for...
Ultragenyx Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Update
16 févr. 2023 16h01 HE
|
Ultragenyx Pharmaceutical Inc.
2022 Total Collaboration and Product Revenue of $355.6 million, Crysvita® revenue of $279.4 million and Dojolvi® revenue of $55.6 million 2023 expected Total Revenue guidance between $425 million to...
Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2022 Financial Results and Corporate Update
09 févr. 2023 16h01 HE
|
Ultragenyx Pharmaceutical Inc.
NOVATO, Calif., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for...
Ultragenyx Reports Preliminary 2022 Revenue; Guidance for 2023 Revenue and Cash Usage; Pipeline Updates and 2023 Milestones
06 janv. 2023 16h01 HE
|
Ultragenyx Pharmaceutical Inc.
Preliminary 2022 Total Product Revenue of $352 million to $356 million, Crysvita® Revenue in Ultragenyx Territories1 of $257 million to $258 million and Dojolvi® revenue of $55 million to $56 million ...
Ultragenyx to Present at the 41st Annual J.P. Morgan Healthcare Conference
04 janv. 2023 06h00 HE
|
Ultragenyx Pharmaceutical Inc.
NOVATO, Calif., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for...
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
21 déc. 2022 16h01 HE
|
Ultragenyx Pharmaceutical Inc.
NOVATO, Calif., Dec. 21, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for...
Ultragenyx to Present at Piper Sandler Healthcare Conference
22 nov. 2022 16h01 HE
|
Ultragenyx Pharmaceutical Inc.
NOVATO, Calif., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for...
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
18 nov. 2022 16h05 HE
|
Ultragenyx Pharmaceutical Inc.
NOVATO, Calif., Nov. 18, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for...